Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein

Neoplasia

Volumn 6, Issue 4, 2004, Pages 354-363

  Li, Yiwei ^a   Che, Mingxin ^a   Bhagat, Sunita ^a   Ellis, Kerrie Lynn ^a   Kucuk, Omer ^a   Doerge, Daniel R ^b   Abrams, Judith ^a   Cher, Michael L ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Bone metastasis; Gene expression; Genistein; Microarray; Prostate cancer

Indexed keywords

GELATINASE B; GENISTEIN; MATRIX METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE TUMOR; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CELL GROWTH; CONTROLLED STUDY; DIET; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR GROWTH; UPREGULATION;

EID: 3142689585     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.03478     Document Type: Article

References (45)

1. American Cancer Society (2003). Cancer Facts and Figures 2003, American Cancer Society, Inc., (6 pp.) Atlanta, GA.
2. Gopalkrishnan RV, Kang DC, and Fisher PB (2001). Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 189, 245-256.
3. Blanco FJ Jr, Wood DP Jr, Gomes DO, Nemeth JA, Beaman AA, and Cher ML (2001). Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 49, 235-242.
4. Goltzman D (1997). Mechanisms of the development of osteoblastic metastases. Cancer 80, 1581-1587.
5. Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593.
6. Chung LW (2003). Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 97, 772-778.
7. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, and Pienta KJ (2003). Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97, 739-747.
8. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, and Ochiai A (2003). Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63, 2096-2102.
9. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, and Keller ET (2001). Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107, 1235-1244.
10. Curran S and Murray GI (1999). Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189, 300-308.
11. John A and Tuszynski G (2001). The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23.
12. Curran S and Murray GI (2000). Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36, 1621-1630.
13. Duffy MJ, Maguire TM, Hill A, McDermott E, and O'Higgins N (2000). Metalloproteinases role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2, 252-257.
14. Nemeth JA, Yousil R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, and Cher ML (2002). Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94, 17-25.
15. Winding B, NicAmhlaoibh R, Misander H, Hoegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brunner N, and Delaisse JM (2002). Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8, 1932-1939.
16. Goltzman D (2001). Osteolysis and cancer. J Clin Invest 107, 1219-1220.
17. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, and Adlercreutz T (1995). Soybean phytoestrogen intake and cancer risk. J Nutr 125, 757S-770S.
18. Barnes S (1995). Effect of genistein on in vitro and in vivo models of cancer. J Nutr 125, 777S-783S.
19. Li Y, Upadhyay S, Bhuiyan M, and Sarkar FH (1999). Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18, 3166-3172.
20. Davis JN, Kucuk O, and Sarkar FH (1999). Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35, 167-174.
21. Li Y and Sarkar FH (2002). Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via akt signaling pathway. Clin Cancer Res 8, 2369-2377.
22. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, and Elgavish A (2001). Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61, 6777-6782.
23. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, and Clinton SK (1999). Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129, 1628-1635.
24. Santibanez JF, Navarro A, and Martinez J (1997). Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 17, 1199-1204.
25. Li Y and Sarkar FH (2002). Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186, 157-164.
26. Li Y and Sarkar FH (2002). Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 132, 3623-3631.
27. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, and Cher ML (1999). Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59, 1987-1993.
28. Holm S (1979). A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65-70.
29. Holder CL, Churchwell MI, and Doerge DR (1999). Quantification of soy isoflavones, genistein and daidzein, and conjugates in rat blood using LC/ES-MS. J Agric Food Chem 47, 3764-3770.
30. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
31. Khatri P, Draghici S, Ostermeier GC, and Krawetz SA (2002). Profiling gene expression using Onto-Express. Genomics 79, 266-270.
32. King RA and Bursill DB (1998). Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67, 867-872.
33. Xu X, Wang HJ, Murphy PA, and Hendrich S (2000). Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 130, 798-801.
34. Ben Yehudah A, Aqeilan R, Robashkevich D, and Lorberboum-Galski H (2003). Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 9, 1179-1190.
35. Nakajima H, Park HL, and Henkart PA (1995). Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin. J Exp Med 181, 1037-1046.
36. Hammond EM, Brunet CL, Johnson GD, Parkhill J, Milner AE, Brady G, Gregory CD, and Grand RJ (1998). Homology between a human apoptosis specific protein and the product of APG5, a gene involved in autophagy in yeast. FEBS Lett 425, 391-395.
37. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S, and Colburn NH (1999). Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 96, 14037-14042.
38. Kumar R (2002). New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens 11, 547-553.
39. Vihinen P and Kahari VM (2002). Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99, 157-166.
40. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, and Boyle WJ (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
41. Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, and Lacey DL (2000). Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 18, 967-976.
42. Croucher PI, Shipman CM, Van Camp B, and Vanderkerken K (2003). Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97, 818-824.
43. Rabbani SA and Mazar AP (2001). The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin North Am 10, 393-415.
44. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, and O'Brien TJ (2001). Increased expression of protease M in ovarian tumors. Tumour Biol 22, 11-18.
45. D'Andrea MR, Derian CK, Santulli RJ, and Andrade-Gordon P (2001). Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 158, 2031-2041.